Results 121 to 130 of about 41,447 (182)
RNF6 promotes chronic myelogenous leukemia cell proliferation and migration by stabilizing vimentin via multiple atypical ubiquitinations. [PDF]
Genes DisZhang H +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 2001
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+8 more sources
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+8 more sources
Current Opinion in Hematology, 1995
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Hematology, 2002
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
Chronic Myelogenous Leukemia in Childhood
Current Oncology Reports, 2021Chronic myelogenous leukemia (CML) is rare in children, requiring extrapolation from treatment of adults. In this review, we explore similarities and differences between adult and pediatric CML with a focus on therapeutic advances and emerging clinical questions.Pediatric CML is effectively treated with long-term targeted therapy using tyrosine kinase ...
Stephanie M. Smith +2 more
openaire +2 more sources